Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors

European Journal of Medicinal Chemistry

Volumn 74, Issue , 2014, Pages 574-605

  Patel, Bhumika D ^a   Ghate, Manjunath D ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

Diabetes; Dipeptidyl peptidase 4; Glucagon like peptide (GLP) 1; Non peptidomimetics; Peptidomimetics

Indexed keywords

2 CYANO PYRROLIDINE DERIVATIVE; ALKENE DERIVATIVE; BETA PHENETHYLAMINE INHIBITOR; BORONIC ACID DERIVATIVE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FLUORINATED PYRROLIDINE AMIDE; FLUORO OLEFIN DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; IMIDAZOLE DERIVATIVE; IMIDAZOPYRAZINONE DERIVATIVE; INCRETIN; OXADIAZOLE DERIVATIVE; OXAZOLOPYRAZINONE DERIVATIVE; PEPTIDOMIMETIC AGENT; PEPTIDOMIMETIC INHIBITOR; PHOSPHONIC ACID DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN INHIBITOR; PYRAZOLINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLIDINE BASED INHIBITOR; PYRROLIDINE DERIVATIVE; SULFONAMIDE; THIAZOLE DERIVATIVE; THIAZOLIDINE DERIVATIVE; TRIAZOLOPIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE DERIVATIVE;

DRUG ACTIVITY; DRUG BINDING SITE; DRUG SENSITIVITY; ELECTROPHILICITY; REVIEW;

DIABETES; DIPEPTIDYL PEPTIDASE-4; GLUCAGON LIKE PEPTIDE (GLP)-1; NON-PEPTIDOMIMETICS; PEPTIDOMIMETICS;

DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS;

EID: 84894175214     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.12.038     Document Type: Short Survey

References (312)

1. International Diabetes Federation - Diabetes Atlas sixth ed. 2013 The Global Burden 29 50 http://www.idf.org/diabetesatlas/download-book (accessed 26.12.13)
2. American Diabetes Association Diagnosis and classification of diabetes mellitus Diabetes Care 33 2010 S62 S69
3. T. Scully Diabetes in numbers Nat. Outlook: Diabetes 485 2012 S2 S3
4. P. Shetty India's diabetes time bomb Nat. Outlook: Diabetes 485 2012 S14 S16
5. K. Benhalima, C. Mathieu, Challenges in the Management of Hyperglycaemia in Type 2 Diabetes. IDF Diabetes Atlas. fourth ed.4th edition, 1-7.
6. A.A. Tahrani, C.J. Bailey, S.D. Prato, and A.H. Barnett Management of type 2 diabetes: new and future developments in treatment Lancet 378 2011 182 197
7. M.J. Theodorakis, O. Carlson, and S. Michopoulo et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP Am. J. Physiol. Endocrinol. Metab. 290 2006 E550 E559
8. J.A. Ehses, V.R. Casilla, and T. Doty et al. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase Endocrinology 144 2003 4433 4445 (Pubitemid 37204843)
9. L. Farilla, A. Bulotta, and B. Hirshberg et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets Endocrinology 144 2003 5149 5158 (Pubitemid 37476040)
10. R. Perfetti, J. Zhou, M.E. Doyle, and J.M. Egan Glucagon-like peptide-1 induces cell proliferation and pancreatic- duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats Endocrinology 141 2000 4600 4605 (Pubitemid 32055138)
11. L.L. Kjems, J.J. Holst, A. Volund, and S. Madsbad The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects Diabetes 52 2003 380 386 (Pubitemid 36173193)
12. C.F. Deacon, M.A. Nauck, and J. Meier et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide J. Clin. Endocrinol. Metab. 85 2000 3575 3581
13. T. Vilsboll, H. Agerso, T. Krarup, and J.J. Holst Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects J. Clin. Endocrinol. Metab. 88 2003 220 224 (Pubitemid 36115169)
14. J.J. Meier, M.A. Nauck, and D. Kranz et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects Diabetes 53 2004 654 662 (Pubitemid 38270634)
15. V.K. Hopsu-Havu, and S.S. Sarimo Purification and characterization of an aminopeptidase hydrolysing glycyl-proline-naphthylamide Hoppe Seylers Z. Physiol. Chem. 384 1967 1540 1550
16. M. Engel, T. Hoffmann, and S. Manhart et al. Rigidity and flexibility of dipeptidyl peptidase IV: crystal structures of and docking experiments with DPIV J. Mol. Biol. 355 2006 768 783 (Pubitemid 41817635)
17. A.D. Kshirsagar, and A.S. Aggarwal et al. DPP IV inhibitors: successes, failures and future prospects Diabetes Metab. Syndr. 5 2011 105 112
18. C.A. Abbott, E. Baker, and G.R. Sutherland et al. Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene Immunogenetics 40 1994 31 38
19. B. Kuhn, M. Hennig, and P. Mattei Molecular recognition of ligands in dipeptidyl peptidase IV Curr. Top. Med. Chem. 7 2007 609 619 (Pubitemid 46488283)
20. R. Mentlein Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides Regul. Pept. 85 1999 9 24 (Pubitemid 29505281)
21. Ahren DPP-4 inhibitors Best. Pract. Res. Clin. Endocrinol. Metab. 21 2007 517 533 (Pubitemid 350185859)
22. H.B. Rasmussen, S. Branner, F.C. Wiberg, and N. Wagtmann Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog Nat. Struct. Biol. 10 2003 19 25 (Pubitemid 36034172)
23. R. Thoma, B. Loeffler, M. Stihle, W. Huber, A. Ruf, and M. Hennig Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV Structure 11 2003 947 959 (Pubitemid 36966784)
24. C.H. Chien, L.H. Huang, C.Y. Chou, and Y.S. Chen et al. One site mutation disrupts dimer formation in human DPP-IV proteins J. Biol. Chem. 279 2004 52338 52345
25. S.R. Shah, R. Bahekar, P. Jadav, D. Patel, and A. Joharapurkar et al. Long-acting peptidomimetics based DPP-IV inhibitors Bioorg. Med. Chem. Lett. 22 2012 3516 3521
26. M. Nabeno, F. Akahoshi, and H. Kishida et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site, Biochem Biophys. Res. Commun. 434 2013 191 196
27. Oefner, A. D'Arcy, and A.M. Sweeney et al. High resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[({2-[(5- iodopyridin-2-yl)amino]-ethyl}-amino)-acetyl]-2-cyano-(S)-pyrrolidine Acta Crystallogr. Sect. D. 59 2003 1206 1212 (Pubitemid 36872357)
28. M. Engel, T. Hoffmann, L. Wagner, and M. Wermann et al. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism Proc. Natl. Acad. Sci. U.S.A. 100 2003 5063 5068 (Pubitemid 36542658)
29. G. Abbenante, and D.P. Fairlie Protease inhibitors in the clinic Med. Chem. 1 2005 71 104
30. N.S. Kang, J.H. Ahn, S.S. Kim, C.H. Chae, and S. Yoo Docking-based 3D-QSAR study for selectivity of DPP4, DPP8, and DPP9 inhibitors Bioorg. Med. Chem. Lett. 17 2007 3716 3721 (Pubitemid 46901103)
31. I.L. Lu, S.J. Lee, H. Tsu, and S.Y. Wu et al. Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors Bioorg. Med. Chem. Lett. 15 2005 3271 3275 (Pubitemid 40799072)
32. C. Rummey, and G. Metz Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site Proteins: Struct. Funct. Bioinform. 66 2007 160 171 (Pubitemid 44955988)
33. A.E. Weber Dipeptidyl peptidase IV inhibitors for the treatment of diabetes J. Med. Chem. 47 2004 4135 4141 (Pubitemid 39045417)
34. J. White Efficacy and safety of incretin based therapies: clinical trial data J. Am. Pharm. Assoc. 49 2009 S30 S40
35. D.X. Brown, and M. Evans Choosing between GLP-1 receptor agonists & DPP-4 inhibitors: a pharmacological perspective J. Nutr. Metab. 2012 10.1155/2012/381713
36. L. Thomas, M. Eckhardt, E. Langkopf, M. Tadayyon, F. Himmelsbach, and M. Mark (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin- 2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors J. Pharmacol. Exp. Ther. 325 2008 175 182 (Pubitemid 351439162)
37. C.F. Deacon Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review Diabetes Obes. Metab. 13 2011 7 18
38. A.J. Bergman, C. Stevens, and Y. Zhou et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers Clin. Ther. 28 2006 55 72 (Pubitemid 43254990)
39. European Medicines Agency (EMEA) Galvus (vildagliptin) - European public assessment report (EPAR) - scientific discussion Available from: URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/galvus/H-771-en6.pdf (accessed 05.07.10)
40. Y.L. He, Y. Wang, and J.M. Bullock et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT J. Clin. Pharmacol. 47 2007 633 641 (Pubitemid 46632151)
41. E.B. Villhauer, J.A. Brinkman, and G.B. Naderi et al. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties J. Med. Chem. 46 2003 2774 2789 (Pubitemid 36702545)
42. European Medicines Agency (EMEA). Onglyza (Ssaxagliptin) - European Public Assessment Report (EPAR) - CHMP Assessment Report. Available from: URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/onglyza/H-1039-en6.pdf (accessed 05.07.10).
43. D.W. Boulton, and M. Geraldes Safety, tolerability, pharmacokinetics and pharmacodynamics of once daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects (poster 0606-P) Diabetes 56 2007 A161
44. P. Covington, R. Christopher, and M. Davenport et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes Clin. Ther. 30 2008 499 512 (Pubitemid 351483925)
45. T. Heise, E.U. Graefe-Mody, S. Huttner, and A. Ring et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients Diabetes Obes. Metab. 11 2009 786 794
46. G.R. Lankas, B. Leiting, and R.S. Roy et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9 Diabetes 54 2005 2988 2994 (Pubitemid 41401097)
47. D. Reinhold, A. Goihl, and S. Wrenger et al. Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice Clin. Chem. Lab. Med. 47 2009 268 274
48. B.F. Burkey, P.K. Hoffmann, U. Hassiepen, J. Trappe, M. Juedes, and J.E. Foley Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited Diabetes Obes. Metab. 10 2008 1057 1061
49. J. Wu, H. Tang, T. Yeh, and C. Chen et al. Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor Biochem. Pharmacol. 78 2009 203 210
50. M.S. Kirby, A. Wang, and C. Dorso et al. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor BMC Pharmacol. 12 2012 2 12
51. R. Andukuri, A. Drincic, and M. Rendell Alogliptin: a new addition to the class of DPP-4 inhibitors Diabetes Metab. Syndr. Obes. 2 2009 117 126
52. M.S. Kirby, C. Dorso, and A. Wang et al. In vitro enzymologic characteristics of saxagliptin, a highly potent and selective DPP4 inhibitor with ''slow binding'' characteristic (Abstract) Clin. Chem. Lab. Med. 46 2008 A79
53. P. O'Brien, and B.F. O'Connor Seprase: an overview of an important matrix serine protease Biochim. Biophys. Acta 1784 2008 1130 1145
54. J. Larsen, B. Hylleberg, K. Ng, and P. Damsbo Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment Diabetes Care 24 2001 1416 1421 (Pubitemid 33716430)
55. M. Pal, and S.H. Havale Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes Bioorg. Med. Chem. 17 2009 1783 1802
56. S.L. Gwaltney II Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV Curr. Top. Med. Chem. 8 2008 1545 1552
57. Y. Liu, Y. Hu, and T. Liu Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects Curr. Med. Chem. 19 2012 3982 3999
58. I. Brandt, J. Joossens, and X. Chen et al. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile) Biochem Pharmacol. 70 2005 134 143 (Pubitemid 40797877)
59. B.F. Burkey, M. Russell, K. Wang, J. Trappe, and T.E. Hughes Vildagliptin displays slow tight-binding to dipeptidyl peptidase (DPP)-4, but not DPP-8 or DPP-9 (Abstract 0788) Diabetologia 49 2006 477
60. Y.B. Kim, L.M. Kopcho, and M.S. Kirby et al. Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118) Arch. Biochem Biophys. 445 2006 9 18 (Pubitemid 41821056)
61. W. Paul DPP-IV Inhibition: promising therapy for the treatment of type 2 diabetes Prog. Med. Chem. 45 2007 71 73
62. X. Wang, Y. Wu, L. Wang, and B. Zhang et al. Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors Eur. J. Med. Chem. 44 2009 3318 3322
63. D.R. Magnin, J.A. Robl, R.B. Sulsky, and D.J. Augeri et al. Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of α-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors J. Med. Chem. 47 2004 2587 2598 (Pubitemid 38580095)
64. W.-T. Jiaang, T.-Y. Tsai, T. Hsu, and C.-T. Chen et al. Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 19 2009 1908 1912
65. D.J. Augeri, J.A. Robl, D.A. Betebenner, and D.R. Magnin et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 48 2005 5025 5037 (Pubitemid 41033142)
66. H. Fukushima, A. Hiratate, M. Takahashi, and A. Mikami et al. Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. 16 2008 4093 4106 (Pubitemid 351484008)
67. C.-T. Chen, W.-T. Jiaang, T.-K. Yeh, and T.-Y. Tsai et al. (2S,4S)-1-[2-(1,1-Dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl] -4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV Bioorg. Med. Chem. Lett. 20 2010 3596 3600
68. T.-Y. Tsai, T. Hsu, C.-T. Chen, J.-H. Cheng, and T.-K. Yeh et al. Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. 17 2009 2388 2399
69. C.D. Haffner, D.L. McDougald, A.S. Randhawa, S.M. Reister, et al., Fluoropyrrolidines as Ddipeptidyl Ppeptidase Iinhibitors, Jan 9 (2003)WO 2003002531.
70. J.A. Sattigeri, M.M.S. Andappan, K. Kishore, and S. Thangathirupathy et al. Discovery of conformationally rigid 3-azabicyclo[3.1.0]hexane-derived dipeptidyl peptidase-IV inhibitors Bioorg. Med. Chem. Lett. 18 2008 4087 4091
71. P.C. Tang, Z.G. Lin, Y. Wang, F.L. Yang, and Q. Wang Design and synthesis of DPP-4 inhibitor for the treatment of type 2 diabetes Chin. Chem. Lett. 21 2010 253 256
72. T. Kondo, I. Sugimoto, T. Nekado, and K. Ochi et al. Design and synthesis of long-acting inhibitors of dipeptidyl peptidase IV Bioorg. Med. Chem. 15 2007 2715 2735 (Pubitemid 46367700)
73. Z. Pei, X. Li, K. Longenecker, T.W. Von Geldern, and P.E. Wiedeman et al. Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors J. Med. Chem. 49 2006 3520 3535 (Pubitemid 43902459)
74. W.T. Jiaang, H. Tsu, X. Chen, and C.T. Chen et al. 2-[3-[2-[(2S)-2-Cyano- 1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]-1,2,3,4- tetrahydroisoquinoline: a potent, selective, and orally bioavailable dipeptidederived inhibitor of dipeptidyl peptidase IV J. Med. Chem. 49 2006 373 380 (Pubitemid 43077350)
75. N. Kato, M. Oka, T. Murase, M. Yoshida, and M. Sakairi et al. Synthesis and pharmacological characterization of potent, selective, and orally bioavailable isoindoline class dipeptidyl peptidase IV inhibitors Org. Med. Chem. Lett. 1 2011 1 7
76. N. Kato, M. Oka, T. Murase, M. Yoshida, M. Sakairi, and S. Yamashita Discovery and pharmacological characterization of N-[2-({2-[(2S)-2- cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2- methylpyrazolo[1,5-a] pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor Bioorg. Med. Chem. 19 2011 7221 7227
77. P. Van der Veken, K. Senten, and I. Kertesz et al. Fluoro-olefins as peptidomimetic inhibitors of dipeptidyl peptidases J. Med. Chem. 48 2005 1768 1780 (Pubitemid 40396310)
78. J. Lin, P.J. Toscano, and J.T. Welch Inhibition of dipeptidyl peptidase IV by fluoroolefin-containing N-peptidyl-O-hydroxylamine peptidomimetics Proc. Natl. Acad. Sci. U.S.A. 95 1998 14020 14024
79. K. Zhao, D.S. Lim, T. Funaki, and J.T. Welch Inhibition of dipeptidyl peptidase IV (DPP IV) by 2-(2-amino-1-fluoro-propylidene)- cyclopentanecarbonitrile, a fluoroolefin containing peptidomimetic Bioorg. Med. Chem. 11 2003 207 215 (Pubitemid 35418263)
80. J. Coutts, T.A. Kelly, R.J. Snow, and C.A. Kennedy et al. Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides J. Med. Chem. 39 1996 2087 2094
81. Belyaev, X. Zhang, K. Augustyns, and A.-M. Lambeir et al. Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors J. Med. Chem. 42 1999 1041 1052 (Pubitemid 29153433)
82. K. Senten, L. Daniels, and P. Van der Veken et al. Rapid parallel synthesis of dipeptide diphenyl phosphonate esters as inhibitors of dipeptidyl peptidases J. Comb. Chem. 5 2003 336 344 (Pubitemid 37140580)
83. W. William, S.E. Bachovchin, J.H. Poplawski, and D.G. Lai et al. Pro-Soft Val-boroPro: a strategy for enhancing in vivo performance of boronic acid inhibitors of serine proteases J. Med. Chem. 54 2011 2022 2028
84. R.J. Snow, and W.W. Bachovchin Boronic acid inhibitors of dipeptidyl peptidase IV: a new class of immunosuppressive Adv. Med. Chem. 3 1995 149 177
85. T.A. Kelly, J. Adams, W.W. Bachovchin, and R.W. Barton et al. Immunosuppressiveboronic acid dipeptides: correlation between conformation and activity J. Am. Chem. Soc. 115 1993 12637 12638 (Pubitemid 24077513)
86. R.J. Snow, W.W. Bachovchin, R.W. Barton, and S.J. Campbell et al. Studies on proline boronic acid dipeptide inhibitors of dipeptidyl peptidase IV: identification of a cyclic species containing a B-N bond J. Am. Chem. Soc. 116 1994 10860 10869
87. B. Boduszek, J. Oleksyszyn, C. Kam, and J. Selzler et al. Dipeptide phosphonates as inhibitors of dipeptidyl peptidase IV J. Med. Chem. 37 1994 3969 3976 (Pubitemid 24379686)
88. K. Senten, P. Van der Veken, I. De Meester, and A.-M. Lambeir et al. Design, synthesis, and SAR of potent and selective dipeptide-derived inhibitors for dipeptidyl peptidases J. Med. Chem. 46 2003 5005 5014 (Pubitemid 37352037)
89. D.M. Evans Dipeptidyl peptidase IV inhibitors Idrugs 5 2002 577 585 (Pubitemid 37214117)
90. E. Schoen, I. Norn, and H.U. Demuth et al. Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes Biol. Chem. Hoppe-Seyler 372 1991 305 311
91. E.R. Parmee, J. He, A. Mastracchio, S.D. Edmondson, and L. Colwell et al. 4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 14 2004 43 46 (Pubitemid 38016208)
92. Y. Kondo, T. Nekado, I. Sugimoto, and K. Ochi et al. Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group Bioorg. Med. Chem. 16 2008 1613 1631 (Pubitemid 351226600)
93. H. Sakashita, F. Akahoshi, H. Kitajima, R. Tsutsumiuchi, and Y. Hayashi [(S)-γ-(Arylamino)prolyl]thiazolidine compounds as a novel series of potent and stable DPP-IV inhibitors Bioorg. Med. Chem. 14 2006 3662 3671
94. T. Yoshida, F. Akahoshi, H. Sakashita, and S. Sonda et al. Fused bicyclic heteroarylpiperazine-substituted L-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electrophilic nitrile group Bioorg. Med. Chem. 20 2012 5033 5041
95. T. Yoshida, F. Akahoshi, and H. Sakashita et al. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H- pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes Bioorganic Med. Chem. 20 2012 5705 5719
96. Miyako Kishimoto Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes Diab. Metab. Synd. Obes. Target. Ther. 6 2013 187 195
97. H.H. Huang, B. Han, J.L. Liu, and Y. Huan et al. Design, synthesis and primary activity of thiomorpholine derivatives as DPP-IV inhibitors Chin. Chem. Lett. 23 2012 297 300
98. C.G. Caldwell, P. Chen, J. He, and E.R. Parmee et al. Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 14 2004 1265 1268 (Pubitemid 38229869)
99. K.J.L. Augustyns, A.M. Lambeir, M. Borloo, and I. De Meester et al. Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV Eur. J. Med. Chem. 32 1997 301 309 (Pubitemid 27220261)
100. S.D. Edmondson, A. Mastracchio, R.J. Mathvink, and J. He et al. (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4] triazolo[1,5-a]- pyridin-6-ylphenyl)butanamide: a selective α-amino amide dpeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 49 2006 3614 3627 (Pubitemid 43902466)
101. D.E. Kaelin, A.L. Smenton, G.J. Eiermann, and H. He et al. 4-Arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV Bioorg. Med. Chem. Lett. 17 2007 5806 5811 (Pubitemid 47446228)
102. M.J. Ammirati, K.M. Andrews, D.D. Boyer, and A.M. Brodeur et al. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl) -pyrrolidin-2-yl] methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor Bioorg. Med. Chem. Lett. 19 2009 1991 1995
103. L. Zhang, M. Su, J. Li, and X. Ji et al. Design, synthesis, structure-activity relationships, and docking studies of 1-(γ-1,2,3- triazol substituted prolyl)-(S)-3,3-difluoropyrrolidines as a novel series of potent and selective dipeptidyl peptidase-4 inhibitors Chem. Biol. Drug. Des. 81 2013 198 207
104. D. Ferraris, Y.S. Ko, D. Calvin, and T. Chiou et al. Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase IV (DPP IV) inhibitors Bioorg. Med. Chem. Lett. 14 2004 5579 5583 (Pubitemid 39346349)
105. J. Xu, H.O. Ok, E.J. Gonzalez, and L.F. Colwell Jr. et al. Discovery of potent and selective β-homophenylalanine based dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 14 2004 4759 4762 (Pubitemid 39490304)
106. S.D. Edmondson, A. Mastracchio, M. Beconi, and L.F. Colwell Jr. et al. Potent and selective proline derived dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 14 2004 5151 5155 (Pubitemid 39233384)
107. L.L. Brockunier, J. He, L.F. Colwell Jr., and B. Habulihaz et al. Potent and selective proline derived dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 14 2004 4763 4766 (Pubitemid 39490305)
108. S. Nordhoff, S. Cerezo-Galvez, A. Feurer, and O. Hill et al. The reversed binding of β-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors Bioorg. Med. Chem. Lett. 16 2006 1744 1748 (Pubitemid 43197558)
109. D. Kim, L. Wang, M. Beconi, and G.J. Eiermann et al. (2R)-4-Oxo-4-[3- (trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5- trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase iv inhibitor for the treatment of type 2 Diabetes J. Med. Chem. 48 2005 141 151 (Pubitemid 40105255)
110. D. Kim, J.E. Kowalchick, S.D. Edmondson, and A. Mastracchio et al. Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA™ (sitagliptin phosphate) Bioorg. Med. Chem. Lett. 17 2007 3373 3377 (Pubitemid 46819031)
111. Y. Chen, Z. Shan, M. Peng, and H. Fan et al. Discovery of potent dipeptidyl peptidase IV inhibitors derived from β-aminoamides bearing substituted [1,2,3]-triazolopiperidines for the treatment of type 2 diabetes Bioorg. Med. Chem. Lett. 21 2011 1731 1735
112. P. Lu, G. Song, Y. Zhu, and S. Xia et al. Synthesis, biological assay in vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase IV inhibitors Eur. J. Med. Chem. 45 2010 4953 4962
113. B.J. Lee, H.J. Kim, W.Y. Kwak, and J.P. Min et al. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes Bioorg. Med. Chem. Lett. 21 2011 3809 3812
114. J.H. Ahn, S.S. Kim, W.S. Park, and S.K. Kang et al. Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 21 2011 1366 1370
115. W.T. Ashton, R.M. Sisco, H. Dong, and K.A. Lyons et al. Dipeptidyl peptidase IV inhibitors derived from β-aminoacylpiperidines bearing a fused thiazole, oxazole, isoxazole, or pyrazole Bioorg. Med. Chem. Lett. 15 2005 2253 2258 (Pubitemid 40528402)
116. P. Chen, C.G. Caldwell, R.J. Mathvink, and B. Leiting et al. Imidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes Bioorg. Med. Chem. Lett. 17 2007 5853 5857 (Pubitemid 47446221)
117. S. Nordhoff, S. Cerezo-Galvez, H. Deppe, and O. Hill et al. Discovery of β-homophenylalanine based pyrrolidin-2-ylmethyl amides and sulfonamides as highly potent and selective inhibitors of dipeptidyl peptidase IV Bioorg. Med. Chem. Lett. 19 2009 4201 4203
118. S. Nordhoff, M. Lopez-Canet, B. Hoffmann-Enger, and S. Bulat et al. From lead to preclinical candidate: optimization of β-homophenylalanine based inhibitors of dipeptidyl peptidase IV Bioorg. Med. Chem. Lett. 19 2009 4818 4823
119. S. Nordhoff, S. Bulat, S. Cerezo-Galvez, and O. Hill et al. The design of potent and selective inhibitors of DPP-4: optimization of ADME properties by amide replacements Bioorg. Med. Chem. Lett. 19 2009 6340 6345
120. J.H. Ahn, J.A. Kim, H.M. Kim, and H.M. Kwon et al. Synthesis and evaluation of pyrazolidine derivatives as dipeptidyl peptidase IV (DP-IV) inhibitors Bioorg. Med. Chem. Lett. 15 2005 1337 1340 (Pubitemid 40268987)
121. J.H. Ahn, S.H. Jung, J.A. Kim, and S.B. Song et al. Pyrazolidine derivatives with heteroaryl urea as dipeptidyl peptidase IV inhibitors Chem. Pharm. Bull. 53 2005 1048 1050 (Pubitemid 41327707)
122. J.H. Ahn, M.S. Shin, M.A. Jun, and S.H. Jung et al. Synthesis, biological evaluation and structural determination of β-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors Bioorg. Med. Chem. Lett. 17 2007 2622 2628 (Pubitemid 46509838)
123. M.A. Jun, W.S. Park, S.K. Kang, and K.Y. Kim et al. Synthesis and biological evaluation of pyrazoline analogues with β-amino acyl group as dipeptidyl peptidase IV inhibitors Eur. J. Med. Chem. 43 2008 1889 1902
124. T. Biftu, D. Feng, X. Qian, and G.-B. Liang et al. (3R)-4-[(3R)-3-Amino- 4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes Bioorg. Med. Chem. Lett. 17 2007 49 52 (Pubitemid 44959987)
125. J.H. Ahn, W.S. Park, M.A. Jun, M.S. Shin, and S.S. Kim et al. Synthesis and biological evaluation of triazepane derivatives as DPP-IV inhibitors J. Fluor. Chem. 130 2009 1001 1010
126. P. Chen, C.G. Caldwell, W. Ashton, and J.K. Wub et al. Synthesis and evaluation of [(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]cyclohexanes and 4-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]piperidines as DPP-4 inhibitors Bioorg. Med. Chem. Lett. 21 2011 1880 1886
127. F. Himmelsbach, M. Mark, M. Eckhardt, E. Langkopf, R. Maier, R. Lotz, Xanthine dderivative, pproduction and uuse tthereof as a mmedicament. Sep. 6 (2002)WO 2002/068420 A1.
128. A.B. Kanstrup, L.B. Christiansen, J.M. Lundbeck, C.K. Sams, M. Kristiansen, Purine 2,6-diones wwhich aare iinhibitors of the eenzyme ddipeptidyl ppeptidase IV (DPP-IVIV). Jan 10 (2002)WO 2002/002560 A3R4.
129. M. Eckhardt, E. Langkopf, M. Mark, and M. Tadayyon et al. 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3- methyl-1-(4-methyl-quinazolin-2- ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes J. Med. Chem. 50 2007 6450 6453 (Pubitemid 350309082)
130. M. Eckhardt, N. Hauel, F. Himmelsbach, and E. Langkopf et al. 3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors Bioorg. Med. Chem. Lett. 18 2008 3158 3162 (Pubitemid 351718346)
131. J.M. Sutton, D.E. Clark, S.J. Dunsdon, and G. Fenton et al. Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes Bioorg. Med. Chem. Lett. 22 2012 1464 1468
132. M.B. Wallace, J. Feng, Z. Zhang, and R.J. Skene et al. Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 18 2008 2362 2367 (Pubitemid 351447287)
133. J.-U. Peters, S. Weber, S. Kritter, and P. Weiss et al. Aminomethylpyrimidines as novel DPP-IV inhibitors: a 105-fold activity increase by optimization of aromatic substituents Bioorg Med. Chem. Lett. 14 2004 1491 1493 (Pubitemid 38299435)
134. J.-U. Peters, S. Weber, S. Kritter, and P. Weiss et al. Aminomethylpyridines as DPP-IV inhibitors Bioorg. Med. Chem. Lett. 14 2004 3579 3580 (Pubitemid 38737171)
135. K. Kaczanowska, K.-H. Wiesmuller, and A.-P. Schaffner Design, synthesis, and in vitro evaluation of novel aminomethyl-pyridines as DPP-4 inhibitors ACS Med. Chem. Lett. 1 2010 530 535
136. J.-U. Peters, D. Hunziker, H. Fischer, and M. Kansy et al. An aminomethylpyrimidine DPP-IV inhibitor with improved properties Bioorg. Med. Chem. Lett. 14 2004 3575 3578 (Pubitemid 38737170)
137. R.P. Brigance, W. Meng, A. Fura, and T. Harrity et al. Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes Bioorg Med. Chem. Lett. 20 2010 4395 4398
138. W. Meng, R.P. Brigance, H.J. Chao, and A. Fura et al. Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a] pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors J. Med. Chem. 53 2010 5620 5628
139. Y. Nishio, H. Kimura, S. Tosaki, and E. Sugaru et al. Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore Bioorg Med. Chem. Lett. 20 2010 7246 7249
140. Y. Nishio, H. Kimura, N. Sawada, E. Sugaru, and M. Horiguchi et al. 2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3, 4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5 yl}methyl)-4-fluorobenzonitrile(DSR- 12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A Bioorg Med. Chem. Lett. 19 2011 5490 5499
141. W. Wang, P. Devasthale, A. Wang, and T. Harrity et al. 7-Oxopyrrolopyridine-derived DPP4 inhibitors - mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site Bioorg Med. Chem. Lett. 21 2011 6646 6651
142. T. Biftu, G. Scapin, S. Singh, D. Feng, J. Becker, and G. Doss et al. Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin Bioorg. Med. Chem. Lett. 17 2007 3384 3387 (Pubitemid 46819024)
143. J.M. Cox, B. Harper, A. Mastracchio, B. Leiting, and R.S. Roy et al. Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 17 2007 4579 4583 (Pubitemid 47058943)
144. S.D. Edmondson, A. Mastracchio, J.M. Cox, and G.J. Eiermann et al. Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors Bioorg. Med. Chem. Lett. 19 2009 4097 4101
145. M. Abe, F. Abe, C. Nishimura, and E. Ichimura et al. Sulphostin, a novel inhibitor of dipeptidyl peptidases IV (DPPIV) that stimulates hematopoiesis in mice J. Antibiot. 58 2005 111 117 (Pubitemid 40410232)
146. Z. Pei, X. Li, T.W. von Geldern, D.J. Madar, and K. Longenecker et al. Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 Diabetes J. Med. Chem. 49 2006 6439
147. B.J. Backes, K. Longenecker, G.L. Hamilton, and K. Stewart et al. Pyrrolidine-constrained phenethylamines: the design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit Bioorg. Med. Chem. Lett. 17 2007 2005 2012 (Pubitemid 46367663)
148. Z. Pei, X. Li, T.W. von Geldern, and K. Longenecker et al. Discovery and Structure-Activity relationships of piperidinone- and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase iv inhibitors J. Med. Chem. 50 2007 1983 1987 (Pubitemid 46626607)
149. S.W. Wright, M.J. Ammirati, K.M. Andrews, and A.M. Brodeur et al. (3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization Bioorg. Med. Chem. Lett. 17 2007 5638 5642 (Pubitemid 47391309)
150. K.M. Andrews, D.A. Beebe, J.W. Benbow, and D.A. Boyer et al. 1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5- difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes Bioorg. Med. Chem. Lett. 21 2011 1810 1814
151. G.-B. Liang, X. Qian, T. Biftu, and S. Singh et al. Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor design Bioorg. Med. Chem. Lett. 18 2008 3706 3710 (Pubitemid 351794517)
152. J.W.Benbow, D.W.Piotrowski, Y.Hui, Substituted 3-amino-pyrrolidino-4- lactams as DPP iinhibitors. Dec 27(2007)WO2007148185.
153. T. Lubbers, M. Bohringer, L. Gobbi, M. Hennig, and D. Hunziker 1,3-Disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 17 2007 2966 2970 (Pubitemid 46702649)
154. P. Mattei, M. Boehringer, P. Di Giorgio, and H. Fischer et al. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes Bioorg. Med. Chem. Lett. 20 2010 1109 1113
155. M. Boehringer, H. Fischer, M. Hennig, and D. Hunziker et al. Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 20 2010 1106 1108
156. D. Hosfield, J. Palan, M. Hilgers, and D. Scheibe et al. A fully integrated protein crystallization platform for small-molecule drug discovery J. Struct. Biol. 142 2003 207 217 (Pubitemid 36457902)
157. J. Feng, Z. Zhang, M.B. Wallace, and J.A. Stafford et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV J. Med. Chem. 50 2007 2297 2300 (Pubitemid 46799241)
158. A.B. Kanstrup, C.K. Sams, J.M. Lundbeck, L.B. Christiansen, M. Kristiansen, DPP-4 iinhibiting ppurine dderivatives for the ttreatment of ddiabetes. Jan 16 (2003)WO 2003/004496 A1.
159. F. Himmelsbach,; M.Mark; M.Eckhardt; E.Langkopf; R.Maier; R.Lotz, World patent (2002)2002068420.
160. Z. Zhang, M.B. Wallace, J. Feng, and J.A. Stafford et al. Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV J. Med. Chem. 54 2011 510 524
161. J. Deng, L. Peng, G. Zhang, and X. Lan et al. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes Eur. J. Med. Chem. 46 2011 71 76
162. H. Xie, L. Zeng, S. Zeng, and X. Lu et al. Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization Eur. J. Med. Chem. 52 2012 205 212
163. Y. Banno, Y. Miyamoto, M. Sasaki, S. Oi, and T. Asakawa et al. Identification of 3-Aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase iv inhibitors that form a unique interaction with Lys554 Bioorg. Med. Chem. 19 2011 4953 4970
164. H. Maezaki, Y. Banno, Y. Miyamoto, and Y. Moritou et al. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554 Bioorg. Med. Chem. 19 2011 4482 4498
165. Y. Miyamoto, Y. Banno, T. Yamashita, and T. Fujimoto et al. Discovery of a 3-pyridylacetic acid derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor J. Med. Chem. 54 2011 831 850
166. Y. Miyamoto, Y. Banno, T. Yamashita, and T. Fujimoto et al. Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125 Bioorg. Med. Chem. 19 2011 172 185
167. Y. Ikuma, H. Hochigai, H. Kimura, and N. Nunami et al. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors Bioorg. Med. Chem. 20 2012 5864 5883
168. Y. Hashimoto Thalidomide as a multi-template for development of biologically active compounds Arch. Pharm. Chem. Life. Sci. 341 2008 536 547
169. Y. Hashimoto Structural development of biological response modifiers based on thalidomide Bioorg. Med. Chem. 10 2002 461 479 (Pubitemid 34112438)
170. Y. Hashimoto Structural development of synthetic retinoids and thalidomide-related molecules Cancer Chemother. Pharmacol. 52 2003 S16 S23
171. Y. Hashimoto, A. Tanatani, K. Nagasawa, and H. Miyachi Thalidomide as a target drug and its application as a template for drug design Drugs Future 29 2004 383 391 (Pubitemid 38724680)
172. Y. Hashimoto Novel biological response modifiers derived from thalidomide Curr. Med. Chem. 5 1998 163 178 (Pubitemid 28238487)
173. Y. Hashimoto Structural development of biological response modifiers based on retinoids and thalidomide Mini-Rev. Med. Chem. 2 2002 543 551
174. K. Motoshima, K. Sugita, Y. Hashimoto, and M. Ishikawa Non-competitive and selective dipeptidyl peptidase IV inhibitors with phenethylphenylphthalimide skeleton derived from thalidomide-related α-glucosidase inhibitors and liver X receptor antagonists Bioorg. Med. Chem. Lett. 21 2011 3041 3045
175. E. Giralt, L. Mendieta, and T. Tarrago et al. Recent patents of dipeptidyl peptidase IV inhibitors Expert Opin. Ther. Pat. 21 2011 1693 1741
176. W.-L. Wu, Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors, Jan 10 (2013)WO 2013/6526 A2.
177. M.J. Zacuto, R.F. Dunn, A.J. Moment, J.M. Janey, et al., Process for preparing chiral dipeptidyl peptidase-IV inhibitors, Jan 3 (2013)WO 2013/3250 A1.
178. Nippi, DPP-4 inhibitor, May 10 (2013)WO 2013/65832 A1.
179. F. Himmaelsbach, E. Langkopf, M. Eckhardt, et al., 8-[3-Amino-piperidin- 1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions, May 15 (2012)US 8178541.
180. K. Dugi, F. Himmaelsbach, M. Mark, et al., Uses of DPP-4 inhibitors, July 31 (2012)US 8232281.
181. K. Orita, T. Gotoh, Methods for producing aminoacetylpyrrolidinecarbonitrile derivatives, Mar 27 (2012)US 8143427.
182. K. Orita, T. Gotoh, Methods for producing aminoacetylpyrrolidinecarbonitrile derivatives, Mar 21 (2012)EP 2123636 B1.
183. T. Biftu, D. Feng, X. Qian, et al., Aminotetrahydropyrans as DPP-4 inhibitors for the treatment or prevention of diabetes, Jan 11 (2012)EP 2001883 B1.
184. J.M. Cox, S.D. Edmondson, A. Mastracchio, Fused aminopiperidines as DPP-4 inhibitors for the treatment or prevention of diabetes, Mar 21 (2012)EP 1921917 B1.
185. T. Biftu, A.E. Webner, Aminotetrahydropyrans as DPP-4 inhibitors for the treatment or prevention of diabetes, Apr 18 (2012)EP 2001883 B1.
186. T. Biftu, P. Chen, J.M. Cox, A.E. Webner, Aminotetrahydropyrans as DPP-4 inhibitors for the treatment or prevention of diabetes, Mar 27 (2012)US 8143289.
187. J.M. Cox, H. Dong, Tricyclic heteroaromatic compounds as DPP-4 inhibitors for the treatment or prevention of diabetes, Jan 11 (2012)EP 2094081 B1.
188. R.R. Wilkening, J.M. Apgar, T. Biftu, et al., Substituted aminotetrahydrothiopyrans and derivatives thereof as DPP-4 inhibitors for the treatment of diabetes, Nov 1 (2012)US 2012/277240 A1.
189. S.D. Edmondson, D. Kim, M. Maccoss, et al., Beta-amino heterocyclic dpp inhibitors for the treatment of diabetes, May 1 (2012)US 8168637.
190. T. Yuji, Y. Shinichi, T. Hozumi, et al., DPP-4 inhibitors, July 26 (2012)US 2012/0189611 A1.
191. J. Feng, S.L. Gwaltney, S.W. Kaldor, et al., DPP inhibitors, Sep. 26 (2012)EP 1608317 B1.
192. J. Feng, S.L. Gwaltney, J.A. Stafford, et al., DPP inhibitors, May 8 (2012)US 8173663.
193. J. Feng, S.L. Gwaltney, M.B. Wallace, et al., DPP inhibitors, Jan 10 (2012)US 8093382.
194. J. Feng, S.L. Gwaltney, J.A. Stafford, et al., DPP inhibitors, May 29 (2012)US 8188275.
195. J. Feng, S.L. Gwaltney, J.A. Stafford, et al., DPP inhibitors, Jul 17 (2012)US 8222411.
196. J. Feng, S.L. Gwaltney, J.A. Stafford, et al., DPP inhibitors, Oct 16 (2012)US 8288539.
197. J. Feng, S.L. Gwaltney, J.A. Stafford, et al., DPP inhibitors, Dec 11 (2012)US 8329900.
198. W. Wang, X. Zhao, C. Zou, et al., Certain DPP inhibitors, Jul 5 (2012)WO 2012/88677 A1.
199. W. Wang, X. Zhao, M. Lei, et al., Certain DPP inhibitors, Jul 5 (2012)WO 2012/88680 A1.
200. Wang W, Zhao X, C. Zou, et al., Certain DPP inhibitors, Jul 5 (2012)WO 2012/89122 A1.
201. W. Wang, X. Zhao, M. Lei, et al., Certain DPP inhibitors, Jul 5 (2012)WO 2012/89123 A1.
202. W. Wang, X. Zhao, Q. Yuan, et al., Certain DPP inhibitors, Jul 5 (2012)WO 2012/89127 A1.
203. P. Devasthale, W. Wang, L.G. Haman, et al., Pyrrolopyridine-based inhibitors of DPP-4 and methods, May 9 (2012)EP 1888589 B1.
204. K. Schoenafinger, G. Jaehne, E. Defossa, et al., Substituted 8-aminoalkylthioxanthines and their use as inhibitors of DPP-4, Aug 7 (2012)US 8236810.
205. S. Arora, N. Sinha, P. Nair, et al., Compounds as DPP-4 inhibitors, Dec 25 (2012)US 8338450.
206. M.U. Khan, R.K. Srinivas, V.P. Kaushik, et al., Novel salts of DPP-4 inhibitors, Jun 14 (2012)WO 2012/76973 A3R4.
207. K. Schoenafinger, G. Jaehne, E. Defossa, et al., Substituted, bicyclic 8-pyrrolidinoxanthines, and methods for their use as inhibitors of DPP, Feb 15 (2011)US 7888343 B2.
208. H. Kroth, T. Feuerstein, F. Richter, et al., DPP-4 inhibitors, Dec 13 (2011)US 8076330.
209. Y. Tominaga, S. Yokota, H. Tanaka, et al., DPP-4 inhibitors, Feb 10 (2011)WO 2011/16220 A1.
210. Y. Fukuda, Y. Asahina, K. Ohata, et al., Biocycloester derivative, Nov 8 (2011)US 8053465.
211. J. Feng, S.L. Gwaltney, M.B. Wallace, et al., DPP inhibitors, Jun 14 (2011)US 7960384.
212. R.J. Christopher, P. Covington, DPP inhibitors for treating diabetes, Nov 9 (2011)EP 1942898 B1.
213. T. Asakawa, DPP-4 inhibitors for treating diabetic patients with sulfonylurea secondary failure, Nov 23 (2011)EP 1671649 B1.
214. J. Feng, S.L. Gwaltney, J.A. Stafford, et al., DPP inhibitors, Apr 14 (2011)US 2011/87022 A1.
215. J. Feng, S.L. Gwaltney, M.B. Wallace, et al., DPP inhibitors, Jan 14 (2011)US 7960384.
216. J. Feng, S.L. Gwaltney, J.A. Stafford, et al,. DPP inhibitors, Mar 15 (2011)US 7906523.
217. J. Feng, S.L. Gwaltney, J.A. Stafford, et al., DPP inhibitors, Jan 18 (2011)US 7872124.
218. J.M. Cox, S.D. Edmondson, A. Mastracchio, Fused aminopiperidines as DPP-4 inhibitors for the treatment or prevention of diabetes, May 17 (2011)US 7943615.
219. S.D. Edmondson, A. Mastracchio, J.M. Cox, Fused aminopiperidines as DPP-4 inhibitors for the treatment or prevention of diabetes, Oct 5 (2011)EP 1819674 B1.
220. T. Biftu, D. Feng, X. Qian, et al., Aminocyclohexanes as DPP-4 inhibitors for the treatment of diabetes, Mar 15 (2011)US 7906649.
221. T. Biftu, D. Feng, A.E. Webner, et al., Heterocyclic compounds as DPP-4 inhibitors for the treatment or prevention of diabetes, Sep. 15 (2011)US 2011/224195 A1.
222. J.M. Cox, S.D. Edmondson, B. Harper, A.E. Webner, Aminopiperidines as DPP-4 inhibitors for the treatment or prevention of diabetes, Feb 8 (2011)US 7884104.
223. T. Biftu, C.G. Caldwell, A.E. Webner, et al., Aminotetrahydropyrans as DPP-4 inhibitors for the treatment or prevention of diabetes, Mar 22 (2011)US 7910596.
224. T. Biftu, P. Chen, D. Feng, X. Qian, Aminotetrahydropyrans as DPP-4 inhibitors for the treatment or prevention of diabetes, Mar 10 (2011)WO 2011/28455 A1.
225. W.T. Ashton, C.G. Caldwell, H. Dong, et al., Bicyclic pyrimidines as DPP-4 inhibitors for the treatment or prevention of diabetes, Jun 7 (2011)US 7956061.
226. J.M. Cox, T. Biftu, H.D. Chu, et al., Substituted aminopiperidines as DPP-4 inhibitors for the treatment or prevention of diabetes, Mar 31 (2011)WO 2011/37793 A1.
227. J.D. Hicks, T. Biftu, P. Chen, et al., Substituted seven-membered heterocyclic compounds as DPP-4 inhibitors for the treatment of diabetes, Nov 24 (2011)WO 2011/146358 A1.
228. T. Biftu, P. Chen, D. Feng, A.E. Webner, Substituted 5,6,7,8- tetrahydropyrido[4,3-d]pyrimidines as DPP-4 inhibitors for the treatment or prevention of diabetes, Apr 19 (2011)US 7928112.
229. S.D. Cypes, A.M. Chen, R.R. Ferlita, et al., Phosphoric acid salt of DPP-4 inhibitor, Feb 23 (2011)EP 1654263 B2.
230. H. Kroth, T. Feuerstein, F. Richter, et al., DPP-4 inhibitors, May 12 (2011)US 2011/112051 A1.
231. G. Balasubramanian, S. Sakamuri, G. Singh, et al., DPP-4 inhibitors, Oct 20 (2011)US 2011/257164 A1.
232. W. Meng, L.G. Hamann, R.P. Brigance, Azolopyrimidine-based inhibitors of DPP-4 and methods, Mar 9 (2011)EP 1836206 B1.
233. B.M. Khamar, S. Chandan, R.I. Modi, Novel DPP-4 compounds, Jul 28 (2011)US 2011/183919 A1.
234. M. Boehringer, D.K. Hunziker, H.R. Kuehne, et al., N-substituted pyrrolidin derivatives as DPP-4 inhibitors, Mar 30 (2011)EP 1441719 B1.
235. F. Himmelsbach, M. Mark, M. Eckhardt, et al., Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions, Jul 8 (2010)US 2010/0173916.
236. F. Himmelsbach, M. Mark, M. Eckhardt, et al., Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions, Aug 12 (2010)US 2010/0204250.
237. G. Balasubramanian, S. Sakamuri, G. Singh, et al., DPP-4 inhibitors, Jul 15 (2010)WO 2010/079413 A3R4.
238. W.W. Bachovchin, H-S. Lai, W. Wu, Soft protease inhibitors, and pro-soft forms thereof, Sep. 2 (2010)WO 2010/099537 A1.
239. Akritopoulou-Zanze, D. Darczak, J. Dinges, et al., Pharmaceutical compositions as inhibitors of DPP-4, Mar 2 (2010)US 7671076.
240. S.L. Gwaltney, J.A. Stafford, M.B. Wallace, et al., DPP inhibitors, Jun 8 (2010)US 7732446.
241. L.E. Burgess, S.D. Cowen, S.L. Gwaltney II, et al., DPP inhibitors, Mar 16 (2010)US 7678909.
242. J. Feng, S.L. Gwaltney, B. Lam, Z. Zhang, et al., DPP inhibitors, Nov 2 (2010)US 7825242.
243. J. Feng, S.L. Gwaltney, S.W. Kaldor, et al., DPP inhibitors, Mar 30 (2010)US 7687625.
244. J. Feng, S.L. Gwaltney, J.A. Stafford, Z. Zhang, et al., DPP inhibitors, Aug 24 (2010)US 7781584.
245. S.X. Cao, J. Feng, S.L. Gwaltney, et al., DPP inhibitors, Sep. 7 (2010)US 7790734.
246. Z. Zhang, B.J. Elder, P.K. Isbester, et al., DPP inhibitors, Oct 5 (2010)US 7807689.
247. J. Feng, S.L. Gwaltney, J.A. Stafford, et al., DPP inhibitors, Sep. 14 (2010)US 7795428.
248. J. Feng, S.L. Gwaltney II, S.W. Kaldor, et al., DPP inhibitors, Sep. 7 (2010)US 7790736.
249. J. Feng, S.L. Gwaltney, M.B. Wallace, Z. Zhang, et al., DPP inhibitors, Mar 30 (2010)US 7687638.
250. J. Feng, S.L. Gwaltney II, S.W. Kaldor, et al., DPP inhibitors, May 25 (2010)US 7723344.
251. Y. Fukuda, Y. Asahina, K. Ohata, et al., Biocycloester derivative, Jul 13 (2010)US 7754757.
252. S. Arora, N. Sinha, P. Nair, et al., Novel ccompounds as DPP-4 iinhibitors, Nov 18 (2010)US 2010/291020 A1.
253. J.M. Cox, H. Dong, Tricyclic heteroaromatic compounds as DPP-4 inhibitors for the treatment or prevention of diabetes, Mar 4 (2010)US 2010/56550 A1.
254. T. Biftu, C.G. Caldwell, A.E. Webner, et al., Aminotetrahydropyrans as DPP-4 inhibitors for the treatment or prevention of diabetes, Sep. 16 (2010)US 2010/234403 A1.
255. T. Biftu, P. Chen, J.M. Cox, A.E. Webner, Aminotetrahydropyrans as DPP-4 inhibitors for the treatment or prevention of diabetes, May 13 (2010)US 2010/120863 A1.
256. J.M. Cox, H. Dong, Tricyclic heteroaromatic compounds as DPP-4 inhibitors for the treatment or prevention of diabetes, Dec 21 (2010)US 7855206.
257. S.D. Edmondson, A. Mastracchio, E.R. Parmee, Fused indoles as DPP inhibitors for the treatment or prevention of diabetes, Apr 7 (2010)EP 1635818 B1.
258. T. Biftu, A.E. Webner, Aminotetrahydropyrans as DPP-4 inhibitors for the treatment or prevention of diabetes, Mar 16 (2010)US 7678905.
259. T. Biftu, P. Chen, J.M. Cox, A.E. Webner, Aminotetrahydropyrans as DPP-4 inhibitors for the treatment or prevention of diabetes, May 20 (2010)WO 2010/56708 A1.
260. A.E. Webner, W.T. Ashton, Fused triazole derivatives as DPP-4 inhibitors for the treatment or prevention of diabetes, Jul 14 (2010)EP 1784188 B1.
261. J.M. Cox, S.D. Edmondson, B. Harper, A.E. Webner, Aminopiperidines as DPP-4 inhibitors for the treatment or prevention of diabetes, Sep. 22 (2010)EP 1796669 B1.
262. J. Xu, L. Wei, A. Mastracchio, S.D. Edmondson, 1,2,4-Oxadiazole derivatives as DPP-4 inhibitors for the treatment or prevention of diabetes, Mar 30 (2010)US 7687492.
263. J. Duffy, D.E. Kaelin Jr., A.E. Wener, B.A. Kirk, Cyclohexylalanine derivatives as DPP-4 inhibitors for the treatment or prevention of diabetes, Mar 2 (2010)US 7671073.
264. T. Biftu, P. Chen, D. Feng, A.E. Webner, Substituted [1,2,4]triazolo[1,5- a]pyrazines as DPP-4 inhibitors for the treatment or prevention of diabetes, Oct 12 (2010)US 7812027.
265. L.G. Hamann, A. Khanna, M.S. Kirby, et al., Adamantylglycine based inhibitors of DPP-4 for the treatment of diabetes, Feb 24 (2010)EP 1658066 B9.
266. H. Kroth, T. Feuerstein, F. Richter, et al., DPP-4 inhibitors, Jan 14 (2010)US 2010/9961 A1.
267. P. Aranyi, L. Balazs, I. Bata, et al., Fluoropyrrolidines having DPP enzyme inhibitory activity, Aug 19 (2010)US 2010/210838 A1.
268. P. Aranyi, L. Balazs, I. Bata, et al., Fluoropyrrolidines having DPP enzyme inhibitory activity, Feb 2 (2010)US 7655663.
269. B.M. Khamar, S. Chandan, R.I. Modi, Novel DPP-4 compounds, Mar 18 (2010) WO 2010/29422 A1.
270. A.M. Lambeir, C. Durinx, and S. Scharpe et al. Dipeptidylpeptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV Crit. Rev. Clin. Lab. Sci. 40 2003 209 294 (Pubitemid 36775376)
271. L.L. Baggio, and D.J. Drucker Biology of incretins: GLP-1 and GIP Gastroenterology 132 2007 2131 2157 (Pubitemid 46711096)
272. S. Struyf, P. Proost, D. Schols, and E.D. Clercq et al. CD26/Dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3 J. Immunol. 162 1999 4903 4909 (Pubitemid 29314895)
273. Sedo, J.S. Duke-Cohan, and E. Balaziova et al. Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis? Arthritis Res. Ther. 7 2005 253 269 (Pubitemid 41646256)
274. D. Detel, T. Kehler, and S. Buljevic et al. Is dipeptidyl peptidase IV (DPP IV) associated with inflammation present in human spondyloarthritides and rheumatoid arthritis Croat. Chem. Acta 85 2012 231 238
275. H. Gotoh et al. Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis Clin. Chem. 35 1989 1016 1018 (Pubitemid 19161276)
276. C. Ospelt, J.C. Mertens, and A. Jungel et al. Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritissynovial fibroblasts Arthritis Rheum. 62 2010 1224 1235
277. P.A. Havre, M. Abe, Y. Urasaki, and K. Ohnuma et al. The role of CD26/dipeptidyl peptidase IV in cancer Front. Biosci. 13 2008 1634 1645 (Pubitemid 351599721)
278. J. Sedo, P. Stremenova, and J. Busek Duke-Cohan. Dipeptidyl peptidase-IV and related molecules: markers of malignancy? Expert Opin. Med. Diag. 2 2008 677 689
279. European Public Assessment Report, Januvia - Scientific Discussion. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/januvia/H-722-en6. pdf (accessed 11.01.09).
280. G. Ghersi, Q. Zhao, M. Salamone, and Y. Yeh et al. The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices Cancer Res. 66 2006 4652 4661
281. W.T. Arscott, A.E. LaBauve, V. May, and U.V. Wesley Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation Oncogene 28 2009 479 491
282. B. Pro, and N.H. Dang CD26/dipeptidyl peptidase IV and its role in cancer Histol. Histopathol. 19 2004 1345 1351 (Pubitemid 39386791)
283. T. Stulc, and A. Sedo Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res. Clin. Pr. 88 2010 125 131
284. M.K. Garg, S. Kharb, and A. Pandit Prescribing gliptins: enthusiasm should be coupled with caution Ind. J. Endocrinol. Metab. 16 2012 324 325
285. T. Okerson, and R.J. Chilton The cardiovascular effects of GLP-1 receptor agonists Cardiovasc. Ther. 30 2012 e146 e155
286. P. Anagnostis, V.G. Athyros, F. Adamidou, and A. Panagiotou et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control Diabetes Obes. Metab. 13 2011 302 312
287. G.P. Fadini, and A. Avogaro Cardiovascular effects of DPP-4 inhibition: beyond GLP-1 Vasc. Pharmacol. 55 2011 10 16
288. M.M. Zaruba, H.D. Theiss, M. Vallaster, and U. Mehl et al. Synergy between CD26/DPP IV inhibition and G-CSF improves cardiac function after acute myocardial infarction Cell. Stem Cell. 4 2009 313 323
289. L. Li, and C. Holscher Common pathological processes in Alzheimer disease and type 2 diabetes: a review Brain Res. Rev. 56 2007 384 402 (Pubitemid 350166529)
290. M.D. Amico, C.D. Filippo, and R. Marfella et al. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice Exp. Gerontol. 45 2010 202 207
291. E.H. Thomas, DPP-4 inhibitors for treating neurodegeneration and cognitive disorders, Jan 15 (2009)US 2009/17015 A1.
292. D. Hans-Ulrich, K. Ants, T. Nguyen, et al., DPP-4 inhibitors for the treatment of schizophrenia and depression, May 1 (2012)US 8168199 B2.
293. J.D. Hughes, J. Blagg, D.A. Price, and S. Bailey et al. Physiochemical drug properties associated with in vivo toxicological outcomes Bioorg. Med. Chem. Lett. 18 2008 4872 4875
294. S. Singh, S. Sethi, V. Khanna, and B. Benjamin et al. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes Eur. J. Pharmacol. 652 2011 157 163
295. A.J. Scheen Pharmacokinetics of dipeptidylpeptidase-4 inhibitors Diabetes Obes. Metab. 12 2010 648 658
296. U. Graefe-Mody, S. Retlich, and C. Friedrich Clinical pharmacokinetics and pharmacodynamics of linalglitin Clin. Pharmacokinet. 51 2012 411 427
297. S. Kumar, R. Sharma, and A. Roychowdhury modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective Curr. Med. Chem. 19 2012 3605 3621
298. K. Yoshida, and T. Niwa Quantitative structure-activity relationship studies on inhibition of hERG potassium channels J. Chem. Inf. Model 46 2006 1371 1378 (Pubitemid 43999180)
299. B.-H. Su, M.-Y. Shen, E.X. Esposito, and A.J. Hopfinger et al. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage J. Chem. Inf. Model 50 2010 1304 1318
300. G. Keseru Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods Bioorg. Chem. Med. Lett. 13 2003 2773 2775 (Pubitemid 36851568)
301. M. Song, and M. Clark Development and evaluation of an in silico model for hERG binding J. Chem. Inf. Model 46 2005 392 400
302. Coi, I. Massarelli, L. Murgia, and M. Saraceno et al. Prediction of hERG potassium channel affinity by the CODESSA approach Bioorg. Med. Chem. 14 2006 3153 3159
303. L. Du-Cuny, L. Chen, and S. Zhang A critical assessment of combined ligand- and structure-based approaches to hERG channel blocker modeling J. Chem. Inf. Model 51 2011 2948 2960
304. Cavalli, E. Poluzzi, F. De Ponti, and M. Recanatini Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of hERG K+ channel blockers J. Med. Chem. 45 2002 3844 3853 (Pubitemid 35024289)
305. S. Ekins, W.J. Crumb, R.D. Sarazan, and J.H. Wikel et al. A three-dimensional quantitative stucture-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel J. Pharmacol. Exp. Ther. 301 2002 427 434 (Pubitemid 34429951)
306. + channel blockers Bioorg. Med. Chem. 12 2004 2307 2315 (Pubitemid 38471715)
307. A.M. Aronov Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers J. Med. Chem. 49 2006 6917 6921 (Pubitemid 44749757)
308. R.A. Pearlstein, R.J. Vaz, J. Kang, and X.-L. Chen et al. Characterization of hERG potassium channel inhibition using CoMSIA 3D QSAR and homology modeling approaches Bioorg. Chem. Med. Lett. 13 2003 1829 1835 (Pubitemid 36561175)
309. S. Durdagi, H.J. Duff, and S.Y. Noskov Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG pore domain J. Chem. Inf. Model. 51 2011 463 474
310. G.P.D. Martino, M. Masetti, L. Ceccarini, A. Cavalli, and M. Recanatini An automated docking protocol for hERG channel blockers in press J. Chem. Inf. Model. 11 Dec 2012 10.1021/ci300326d
311. A. Cavalli, R. Buonfiglio, and C. Ianni et al. Computational design and discovery of "minimally structured" hERG blockers J. Med. Chem. 55 2012 4010 4014
312. A.M. Aronov Predictive in-silico modelling for hERG channel blockers Drug. Discov. Today 10 2005 149 155 (Pubitemid 40247813)